DUBLIN, March 3, 2017 /PRNewswire/ --Endo International plc (NASDAQ / TSX: ENDP) today announced that it has applied to the Toronto Stock Exchange (the "TSX") to have its ordinary shares delisted from the TSX at the close of business on March 17, 2017. This application is being made due to the limited trading volume of Endo's ordinary shares on the TSX (less than 1% of the trading in Endo's ordinary shares has occurred on the TSX since the date Endo's ordinary shares were listed on the TSX). Endo's ordinary shares are listed on and primarily trade on NASDAQ. Endo will continue to be a reporting issuer in each of the provinces of Canada following the proposed delisting, and will continue to comply with applicable Canadian securities laws and to file its continuous disclosure documents on SEDAR as required.
About Endo International plc
Endo International plc (NASDAQ / TSX: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering high-quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.
